Abstract
| Language | English |
|---|---|
| Article number | 41 |
| Number of pages | 9 |
| Journal | Frontiers in Pharmacology |
| Volume | 8 |
| DOIs | |
| Publication status | Published - 2 Feb 2017 |
Fingerprint
Keywords
- dengue
- willingness to pay
- vaccine
- consumers
- Brazil
Cite this
}
Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil : implication for future pricing considerations. / Godói, Isabella Piassi; Santos, André Soares; Reis, Edna Afonso; Lovato Pires de Lemos, Livia; Brandão, Cristina Mariano Ruas; Alvares, Juliana; de Assis Acurcio, Francisco; Godman, Brian; Guerra Júnior, Augusto Afonso.
In: Frontiers in Pharmacology , Vol. 8, 41, 02.02.2017.Research output: Contribution to journal › Article
TY - JOUR
T1 - Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil
T2 - Frontiers in Pharmacology
AU - Godói, Isabella Piassi
AU - Santos, André Soares
AU - Reis, Edna Afonso
AU - Lovato Pires de Lemos, Livia
AU - Brandão, Cristina Mariano Ruas
AU - Alvares, Juliana
AU - de Assis Acurcio, Francisco
AU - Godman, Brian
AU - Guerra Júnior, Augusto Afonso
PY - 2017/2/2
Y1 - 2017/2/2
N2 - Introduction and objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public health system, information is need regarding consumers’ willingness to pay for the dengue vaccine in the country as well as discussions related to the possible inclusion of this vaccine into the public health system. This was the objective of this research. Methods: We conducted a cross-sectional study with residents of Greater Belo Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine. Results: 507 individuals were interviewed. These were mostly female (62.4%) had completed high school (62.17%), were working (74.4%), had private health insurance (64.5%) and did not have dengue (67.4%). The maximum median value of consumers’ willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil's regulatory chamber of pharmaceutical products market (CMED) for the commercialization of Dengvaxia® for three doses, only 17% of the population expressed willingness to pay for this vaccine. Conclusion: Brazil is currently one of the largest markets for dengue vaccine and the price established is a key issue. We believe the manufacturer should asses the possibility of lower prices to reach a larger audience among the Brazilian population.
AB - Introduction and objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public health system, information is need regarding consumers’ willingness to pay for the dengue vaccine in the country as well as discussions related to the possible inclusion of this vaccine into the public health system. This was the objective of this research. Methods: We conducted a cross-sectional study with residents of Greater Belo Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine. Results: 507 individuals were interviewed. These were mostly female (62.4%) had completed high school (62.17%), were working (74.4%), had private health insurance (64.5%) and did not have dengue (67.4%). The maximum median value of consumers’ willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil's regulatory chamber of pharmaceutical products market (CMED) for the commercialization of Dengvaxia® for three doses, only 17% of the population expressed willingness to pay for this vaccine. Conclusion: Brazil is currently one of the largest markets for dengue vaccine and the price established is a key issue. We believe the manufacturer should asses the possibility of lower prices to reach a larger audience among the Brazilian population.
KW - dengue
KW - willingness to pay
KW - vaccine
KW - consumers
KW - Brazil
UR - http://journal.frontiersin.org/article/10.3389/fphar.2017.00041/abstract
U2 - 10.3389/fphar.2017.00041
DO - 10.3389/fphar.2017.00041
M3 - Article
VL - 8
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
SN - 1663-9812
M1 - 41
ER -